A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

A method of treating a hyperkeratotic skin condition includes combining contents of a compounded capsule with corticosteroid cream or ointment that includes a high potency corticosteroid to formulate a topical composition for application to a skin area affected by hyperkeratosis. The contents of the capsule may include urea powder, and the corticosteroid cream or ointment may include Clobetasol Propionate Cream or Ointment, Diflorasone Diacetate Cream or Ointment, Amcinonide Cream or Ointment, Betamethasone Dipropionate Cream or Ointment, Desoximetasone Cream or Ointment, Fluocinonide Cream or Ointment, Halcinonide Cream or Ointment, Halobetasol Propionate Cream or Ointment, Mometasone Furoate Cream or Ointment, Flurandrenolide Cream or Ointment, or a combination thereof.

The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.

The present invention resides in the discovery that combined use of kuraridin (or any one of its analogs) and epicatechin gallate (ECG) can provide heightened level of antimicrobial activity, especially for the suppression of bacteria of the Staphylococcus aureus and Staphylococcal species. Compositions, kits, and methods for the combination use are disclosed.

Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

Provided herein are methods for treating metastatic prostate cancer using anti-androgen compounds and radionuclide-labeled androgens.

The present invention relates to budesonide, or a salt thereof, or mixtures thereof for ophthalmic use in a method for the curative treatment of an eye disorder or ailment or disease in a subject in need. Further, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of: (i) a budesonide, or a salt thereof, or mixtures thereof; (ii) at least one suspending/thickening agent, and optionally one or more physiologically and/or pharmacologically acceptable excipients; said composition being for use in a method for the curative treatment of an inflammation of the and ocular adnexa or inflammation of the eyeball in a subject in need.

The present invention relates to budesonide, or a salt thereof, or mixtures thereof for ophthalmic use in a method for the curative treatment of an eye disorder or ailment or disease in a subject in need. Further, the present invention relates to a composition comprising a mixture comprising or, alternatively, consisting of: (i) a budesonide, or a salt thereof, or mixtures thereof; (ii) at least one suspending/thickening agent, and optionally one or more physiologically and/or pharmacologically acceptable excipients; said composition being for use in a method for the curative treatment of an inflammation of the and ocular adnexa or inflammation of the eyeball in a subject in need.

The present disclosure provides pharmaceutical compositions comprising mometasone and diisopropyl adipate (DIPA) for topical administration. These compositions can be formulated as creams, lotions, and foams, and are particularly suitable for administration in hairy skin; for example, for treating inflammatory skin conditions, such as dermatitis, eczema, and psoriasis.

The present disclosure provides pharmaceutical compositions comprising mometasone and diisopropyl adipate (DIPA) for topical administration. These compositions can be formulated as creams, lotions, and foams, and are particularly suitable for administration in hairy skin; for example, for treating inflammatory skin conditions, such as dermatitis, eczema, and psoriasis.